The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone;Wpływ polimorfizmu interleukiny-6 na skuteczność leczenia chorych na reumatoidalne zapalenie stawów metotreksatem i prednizonem

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 3, 2005, Pages 843-847

  Pawlik, Andrzej ^a   Czerny, Bogusław ^a   Da̧browska Zamojcin, Ewa ^a   Górnik, Wanda ^a   Poziomkowska, Iwona ^b   Gawrońska Szklarz, Barbara ^a   Herczyńska, Magdalena ^c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Uniwersytetu Medycznego im Karola Marcinkowskiego   (Poland)

^c Szpital Wojewódzki   (Poland)

Author keywords

Interleukin 6; Polymorphism; Rheumatoid arthritis

Indexed keywords

CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 6; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT OUTCOME;

EID: 33644781616     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kishimoto T., Akira S., Narazaki M. i wsp.: Interleukin-6 family of cytokines and gp130. Blood, 1995, 86, 1243.
2. Ishibashi T., Kimura H., Uchida T. i wsp.: Human interleukin-6 is a direct promoter of maturation of megakaryocytes in vitro. Proc. Natl. Acad. Sci. USA, 1987, 86, 5953.
3. Tamura T., Udagawa N., Takahashi N. i wsp.: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 1993, 90, 11924.
4. Sack U., Kinne R., Marx T. i wsp.: Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int., 1993, 13, 45.
5. Okamoto H., Yamamura M., Marita Y. i wsp.: The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997, 40, 1096.
6. Hoffmann S.C., Stanley E.M., Darrin Cox E. i wsp.: Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation, 2001, 72, 1444.
7. Donn R.P., Barrett J.H., Farhan A. i wsp.: Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. British Pediatric Rheumatology Study Group. Arthritis Rheum., 2001, 44, 802.
8. Ared W.P., Dayer J.M.: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum., 1990, 33, 305.
9. Genestier L., Paillot R., Quemeneur L. i wsp.: Mechanisms of action of methotrexate. Immunopharmacology, 2000, 47, 247.
10. Sperling R.I., Benincaso A.I., Anderson R.J. i wsp.: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum., 1992, 35, 376.
11. Leroux J.L., Damon M., Chavis C. i wsp.: Effects of a single dose of methotrexate on 5- and 12-lipoxygenase products in patients with rheumatoid arthritis. J. Rheumatol., 1992, 19, 863.
12. Hawkes J.S., Cleland L.G., Proudman S.M. i wsp.: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J. Rheumatol., 1994, 21, 55.
13. Conolly K.M., Stecher V.J., Danis E. i wsp.: Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int. J. Immunopharmacol., 1998, 10, 717.
14. Becker C., Barbulescu K., Hildner K. i wsp.: Activation and methrotrexate - mediated supression of the TNF alpha promoter in T cells and macropanges. Ann. N.Y. Acad. Sci., 1998, 859, 311.
15. Hildner K., Finotto S., Becker C. i wsp.: Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol., 1999, 118, 137.
16. Spadaro A., Taccari E., Riccieri V. i wsp.: Relationships of soluble interleukin-2 - receptor and interleukin-6 with class - specific rheumatoid factors during lowdose methotrexate treatment in rheumatoid arthritis. Rev. Rhum. Engl. Ed., 1997, 64, 89.
17. Sung J.Y., Hong J.H., Kang H.S. i wsp.: Methrotrexate suppresses the interleukin-6 induced generation or reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology, 2000, 47, 35.
18. Constantin A., Loubet-Lescoulie P., Lambert N. i wsp.: Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum., 1998, 41, 48.
19. Verhoef C.M., van Roon J.A., Vianen M.E. i wsp.: The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann. Rheum. Dis., 1999, 58, 49.
20. Colotta F., Re F., Muzio M. i wsp.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science, 1993, 261, 472.
21. Bronicki R.A., Backer C.L., Baden H.P. i wsp.: Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann. Thorac. Surg., 2000, 69, 1490.
22. Fishman D., Faulds G., Jeffery R. i wsp.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest., 1998, 102, 1369.
23. Pascual M., Nieto A., Mataran L. i wsp.: IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun., 2000, 1, 338.
24. Dahlqvist S.R., Arlestig L., Sikstrom C. i wsp.: Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden. Arthritis Rheum., 2002, 46, 3096.